Phase II proof of concept clinical trial of voclosporin in the patients with focal segmental glomerulosclerosis (FSGS)and minimal change disease (MCD).
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Voclosporin (Primary)
- Indications Focal segmental glomerulosclerosis; Nephrotic syndrome
- Focus Proof of concept; Therapeutic Use
- 27 Oct 2017 Planned initiation date changed to 1 Jan 2018.
- 27 Oct 2017 New trial record
- 20 Oct 2017 According to an Aurinia Pharmaceuticals media release, this trial is expected to begin in the first half of 2018.